[
  {
    "ts": null,
    "headline": "Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season",
    "summary": "Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% per year, both lagging the broader US market's expected pace. The company’s net profit margin has narrowed to 32.1% from last year’s 33.6%. Over the past five years, earnings have declined by 4.6% per year and the company has reported negative year-over-year earnings growth. See our full analysis for Regeneron Pharmaceuticals. Next, we will see how these results fit with...",
    "url": "https://finnhub.io/api/news?id=3611c83bdffdb77b6e8c517ca3e3c2d57e72245f2ac8c12b62d4c17f47571505",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761833829,
      "headline": "Regeneron (REGN) Margin Compression Reinforces Cautious Community Narratives Heading Into Earnings Season",
      "id": 137269367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% per year, both lagging the broader US market's expected pace. The company’s net profit margin has narrowed to 32.1% from last year’s 33.6%. Over the past five years, earnings have declined by 4.6% per year and the company has reported negative year-over-year earnings growth. See our full analysis for Regeneron Pharmaceuticals. Next, we will see how these results fit with...",
      "url": "https://finnhub.io/api/news?id=3611c83bdffdb77b6e8c517ca3e3c2d57e72245f2ac8c12b62d4c17f47571505"
    }
  },
  {
    "ts": null,
    "headline": "What Catalysts Are Driving the Changing Narrative for Regeneron?",
    "summary": "Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on the heels of new earnings results and momentum within its drug pipeline. The revision reflects updated analyst models that weigh the strength of products like Eylea and Dupixent against evolving challenges in the regulatory and operational landscape. Stay tuned to discover how investors can monitor these ongoing shifts and remain informed as Regeneron's story...",
    "url": "https://finnhub.io/api/news?id=ac10aa6ca602b3fa112edc4816b889337e00957e8e1311486f2fc842dfbb5336",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830084,
      "headline": "What Catalysts Are Driving the Changing Narrative for Regeneron?",
      "id": 137266889,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on the heels of new earnings results and momentum within its drug pipeline. The revision reflects updated analyst models that weigh the strength of products like Eylea and Dupixent against evolving challenges in the regulatory and operational landscape. Stay tuned to discover how investors can monitor these ongoing shifts and remain informed as Regeneron's story...",
      "url": "https://finnhub.io/api/news?id=ac10aa6ca602b3fa112edc4816b889337e00957e8e1311486f2fc842dfbb5336"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
    "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
    "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761816041,
      "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
      "id": 137266210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389349379/image_1389349379.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
      "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9"
    }
  }
]